13.04.2022 15:00:00
|
BioMarin to Host First Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, April 27, at 4:30pm ET
SAN RAFAEL, Calif., April 13, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 27th, at 4:30 p.m. ET to discuss first quarter 2022 financial results and provide a general business update.
BMRN 1Q22 Financial Results April 27, 2022Dial-in Number
U.S. / Canada Dial-in Number: (866) 502-9859
International Dial-in Number: (574) 990-1362
Conference ID: 9770836
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 9770836
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.biomarin.com. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of seven commercialized products and multiple clinical and preclinical product candidates. For additional information, please visit www.biomarin.com. Information on such a website is not incorporated by reference into this press release.
Contacts: | |
Investors | Media |
Traci McCarty | Debra Charlesworth |
BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
(415) 455-7558 | (415) 455-7451 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-first-quarter-2022-financial-results-conference-call-and-webcast-on-wednesday-april-27-at-430pm-et-301524255.html
SOURCE BioMarin Pharmaceutical Inc.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Biomarin Pharmaceutical Inc.mehr Nachrichten
Analysen zu Biomarin Pharmaceutical Inc.mehr Analysen
Aktien in diesem Artikel
Biomarin Pharmaceutical Inc. | 61,14 | -0,29% |